分析沙格列汀联合阿卡波糖治疗初诊老年2型糖尿病疗效

Analysis of the Efficacy of Saxagliptin Combined with Acarbose in the Treatment of Elderly Patients with Type 2 Diabetes

目的观察沙格列汀联合阿卡波糖治疗初诊老年2型糖尿病疗效。方法样本选取时间2015年1月—2017年12月,研究目标为99例2型糖尿病患者,根据治疗措施的差异性随机分为观察组(n=50)和对照组(n=49),对照组予以阿卡波糖治疗,观察组予以沙格列汀+阿卡波糖治疗。治疗12周后对比两组患者血糖控制情况、体质指数、空腹胰岛素、胰岛β细胞功能以及不良反应发生情况。结果观察组空腹血糖、餐后2 h血糖、糖化血红蛋白、体质指数、空腹胰岛素、胰岛β细胞功能分别为(6.81±1.62)mmol/L、(10.03±4.13)mmol/L、(7.28±0.94)%、(26.63±1.25)kg/m^2、(9.96±1.24)m IU/L、(38.24±19.36)%,对照组分别为(8.93±2.21)mmol/L、(14.29±5.38)mmol/L、(8.05±1.33)%、(28.31±1.52)kg/m^2、(9.01±1.27)m IU/L、(45.97±18.55)%,(t=5.451 4、4.424 7、3.331 8、6.011 7、3.765 8、2.027 8,P<0.05);观察组不良反应发生率为2.00%,低于对照组12.24%,(χ~2=3.953 0,P=0.046 7)。结论沙格列汀联合阿卡波糖治疗初诊老年2型糖尿病疗效极佳,在临床治疗过程中可以作为首选措施。

Objective This paper tries to observe the efficacy of saxagliptin combined with aearbose in the treatment of elderly patients with type 2 diabetes. Methods The sample selection time began in January 2015 and ended in Decem- ber 2017. The study subject was 99 patients with type 2 diabetes, and were randomly divided into observation group （n=50） and control group （n=49） according to the differences in treatment measures. The control group was treated with acarbose and the observation group was treated with saxagliptin plus acarbose. After 12 weeks of treatment, blood glu- cose control, body mass index, fasting insulin, pancreatic β-cell function, and occurrence of adverse reactions were compared between the two groups. Results The fasting blood glucose, postprandial blood glucose, glycosylated hemoglobin, body mass index, fasting insulin, and islet β-cell function in the observation group were （6.81±l.62）mmol/L, （10.03±4.13）mmol/L, （7.28±0.94）%, （26.63±1.25）kg/m2, （ 9.96±1.24）mIU/L, （38.24±19.36）%, the control group were （8.93±2.21）MMol/L, （14.29±5.38）MMol/L, （8.05±1.33）%, （28.31±1.52）kg/M2, （9.01±1.27）mIU/L, （45.97±18.55）% ; （t= 5.451 4,4.424 7,3.331 8,6.011 7,3.765 8,2.027 8,P〈0.05）; the incidence of adverse reactions in the observation group was 2.00% lower than the control group,12.24% （X2=3.953 0,P=0.046 7）. Conclusion The combination of saxagliptin and acarbose for the treatment of elderly patients with type 2 diabetes is highly effective and can be used as a first choice in clinical treatment.